Cairo, Egypt – 6th May 2025 – EVA Pharma’s high-containment and biologics sterile facilities have successfully obtained EU-GMP (European Union Good Manufacturing Practice) certification. This accomplishment is a direct result of EVA’s ongoing commitment to innovation and its dedication to the highest global quality standards in the manufacturing of safe and effective healthcare solutions for patients globally. 
 
The EU-GMP approval underlines EVA Pharma’s capacity to manufacture and distribute essential high-potency and biological medications, particularly in the fields of diabetes, oncology, immunology, and anti-infectives. With these certifications, EVA Pharma can meet the growing demand for advanced therapies and fulfill unmet patients’ needs globally. 

Dr. Waheed Wardy, Senior Manufacturing Sites Director at EVA Pharma, commented, “The receipt of EU-GMP certification for our high-containment and biologics facilities represents a key milestone in our ongoing efforts to ensure the highest levels of manufacturing excellence. This achievement does not only reflect our dedication to meeting international standards, but we are eager to explore strategic partnerships and collaborations in the development and production of next-generation high-potency products.” 
 
Dr. Anthony Gamal, Senior Quality Assurance Manager at EVA Pharma, stated, "Throughout the years, EVA Pharma has consistently adhered to quality control and assurance as a fundamental pillar of institutional excellence. This has significantly contributed to obtaining full EU-GMP certification for all the company’s industrial facilities, positioning EVA Pharma as one of Egypt’s leading companies in achieving global accreditations for Egyptian manufacturing." 
 
He added, "This accomplishment opens new horizons for exporting Egyptian medicines globally. It drives us to pursue, with great enthusiasm, continued growth and innovation—ensuring patients worldwide have access to safe and effective medicines." 

This significant achievement enhances EVA Pharma’s capabilities and strengthens its position as a trusted partner for global pharmaceutical companies seeking high-quality manufacturing solutions. The company’s high-containment facility is now ready to serve the global healthcare market with the highest standards of safety, quality, and innovation. 
 
About EVA Pharma  

EVA Pharma is dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access. The company leverages cutting-edge technology at two research centers bringing first-of-its-kind capabilities to the Middle East and Africa including mRNA research and development from AI prediction to biological products.  

With a 5,000-strong team of professionals, EVA Pharma produces more than one million healthcare products a day at four state-of-the-art manufacturing facilities, which are internationally recognized for innovation, and have been approved by multiple regulatory agencies.  

Guided by a relentless drive to ensure sustainable access to pressing yet unmet disease areas, the company’s product portfolio focuses on twelve therapeutic areas: Anti-infectives, metabolic health, bone, neuroscience, oncology, respiratory, gynecology, urology and andrology, pediatrics, ophthalmology, gastrointestinal tract, family medicine to meet both local and international demand.  

EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 70 countries worldwide.  

For more information, please visit: www.evapharma.com & https://www.evapharma.com/newsroom or follow us on Facebook, LinkedIn & Instagram